市場調査レポート
商品コード
1140679
去勢抵抗性前立腺がん治療の世界市場-2022-2029年Global Castrate Resistant Prostate Cancer Therapeutics Market - 2022-2029 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
去勢抵抗性前立腺がん治療の世界市場-2022-2029年 |
出版日: 2022年10月20日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
|
前立腺がんの有病率の増加が市場の成長につながります。
世界的に前立腺がんの罹患率が上昇していることが、前立腺がん治療薬の市場成長に拍車をかけています。前立腺がんは、皮膚がんを除いて、男性に最も多く見られるがんです。Cancer.Net Editorial Boardの推定データによると、2022年に米国で268,490人の男性が前立腺がんと診断されました。Net編集委員会の推計データでは、2020年に1,414,259人が前立腺がんと診断されています。世界で4番目に多く診断されるがんです。米国では男性のがんによる死亡原因の第2位です。2020年に前立腺がんで死亡した人は34,500人で、世界では375,304人が前立腺がんで死亡しています。先進国は発展途上国に比べ、前立腺がん患者の有病率が高いです。がん患者の増加は、死亡リスクを最小限に抑え、ウイルスの腫瘍への影響を低下させるために、去勢抵抗性前立腺がん治療薬の需要増につながります。世界市場の消費者は健康意識が高く、深刻な健康状態を改善するために高額な出費をする用意があります。消費者の平均購買力の伸びと癌の有病率の上昇は、予測期間中、去勢抵抗性前立腺がん治療薬の需要を世界的に促進するでしょう。
去勢抵抗性前立腺がんに対するいくつかの薬物承認は、市場成長の一助となります。去勢抵抗性前立腺がん治療薬のマーケティングに対する政府の注目度は、世界中でかなり高まっています。去勢抵抗性前立腺がん治療市場には、以下のようないくつかの最近の開拓が注目されています。2022年3月、FDAはアンドロゲン受容体(AR)経路阻害およびタキサン系化学療法で治療された転移性去勢抵抗性前立腺がんに対してプルビクトを承認しました。
しかし、去勢抵抗性前立腺がん治療に伴う高コストが、予測期間中の市場成長の主な抑制要因となっています。
予測期間中、北米が支配的な地域です。
2019年の世界の去勢抵抗性前立腺がん治療市場では、北米市場が最大の市場シェアで支配しています。北米市場の成長を増強する要因としては、前立腺がんの発生率と有病率の大幅な上昇、および前立腺がんに対する意識を高めるためのイニシアチブが挙げられます。例えば、米国とカナダでは、毎年9月に前立腺がん啓発月間が実施されています。また、組織は前立腺癌の調査に対して助成金を提供しています。
さらに、アジア太平洋地域は世界市場で最も高いCAGRで成長すると予想されています。これは、この地域における前立腺がんの高い有病率と、中国やインドなどの主要経済国における急速に進化する医療インフラが、前立腺がん治療薬市場の成長に拍車をかけていることに起因します。
去勢抵抗性前立腺がん治療市場は、少数の企業によって支配されています。市場成長の主要なプレーヤーには、アステラス製薬、バイエルAG、ジョンソン&ジョンソンサービス社、ファイザー社、サノフィSA、グラクソ・スミスクラインPLC、ノースウェスト・バイオセラピー、アクティブ・バイオテックABなどです。主要企業は、製品の発売、買収、提携など、いくつかの成長戦略を実行し、それが去勢抵抗性前立腺がん治療薬市場の成長を世界的に押し上げると推定されます。2020年5月、XTANDIは、遠隔転移を有する前立腺がんの治療に使用されることが、日本の厚生労働省によって承認されました。XTANDIは、経口アンドロゲン受容体シグナル阻害剤で、遠隔転移を有する前立腺がん患者の治療薬として使用されます。2022年8月、FDAはバイヤーの前立腺癌治療薬の拡大使用を承認しました。この承認は、第3相ARASENS試験の結果に基づいており、Nubeqaとアンドロゲン除去療法およびドセタキセルを併用した場合、ADTおよびドセタキセルと比較して前立腺がんによる死亡リスクが最大で32%減少することが実証されました。一部の大手企業は、事業拡大のために買収戦略に従っています。例えば、2021年6月、バイエルは前立腺癌のパイプラインを拡大するため、ノリアとPSMAセラピューティクスを買収しました。この買収を通じて、買い手は、アクチニウム225に基づく分化型アルファ放射性核種治験化合物と前立腺特異的膜抗原(PSMA)に向けた低分子の独占権を獲得しました。
COVID-19の影響世界の去勢抵抗性前立腺がん治療市場にネガティブな影響を与えます。
COVID-19の大流行は、2020年の去勢抵抗性前立腺がん治療市場の成長を鈍化させると予想されます。病院受診数の下降による診断率の低下は、2020年の去勢抵抗性前立腺がん治療市場の成長に悪影響を与える大きな要因となっています。
Castrate Resistant Prostate Cancer Therapeutics Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 8.4% during the forecast period (2022-2029).
Castration-resistant prostate cancer is stated as prostate cancer that is scattered to other parts of the body. Several risk factors for castration-resistant prostate cancer include genetic predisposition, unhygienic diet, geriatric population, medication exposure, and many sexual partners. The methods were available to diagnose castration-resistant prostate cancer, including prostate imaging, tumor marker, biopsy, and staging test. For CRPC treatment, docetaxel-based chemotherapy has been widely accepted by urologists and oncologists. The increasing prevalence of prostate cancer, including castration-resistant prostate cancer, augments the market growth. Moreover, the increasing geriatric population is the main driver of the market.
Market Dynamics: The growing prevalence of prostate cancer leads to the market's growth.
The rising incidences of prostate cancer globally are spurring the market growth for prostate cancer therapeutics. Prostate cancer is most common in men, except for skin cancer. According to the data estimated by the Cancer.Net Editorial Board, 268,490 men in the United States were diagnosed with prostate cancer in 2022. According to Net Editorial Board, estimated data of 1,414,259 people were diagnosed with prostate cancer in 2020. It is the fourth most commonly diagnosed cancer in the world. It is the second leading cause of cancer death in men in the United States. There were 34,500 people who died of prostate cancer in 2020, and 375,304 people worldwide died of prostate cancer. Developed nations have a higher prevalence of prostate cancer cases than developing nations. Cancer patients' growth leads to increased demand for castrate-resistant prostate cancer therapeutics to minimize the risk of death and lower the virus's effect on the tumor. The global market consumers are highly health-conscious and ready to spend high amounts to enhance their severe health conditions. The growth in the consumers' average purchasing power and rising cancer prevalence will fuel the demand for castrate-resistant prostate cancer therapeutics globally during the forecast period.
Several drug approvals for castrate-resistant prostate cancer help to grow market growth. The government's focus on marketing castrate-resistant prostate cancer therapeutics is increasing considerably across the globe. There are several recent developments noticed in the castrate-resistant prostate cancer therapeutics market, such as. In March 2022, the FDA approved Pluvicto for metastatic castration-resistant prostate cancer treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
However, the high cost associated with castrate-resistant prostate cancer treatment is the major restraint for the market's growth during the forecast period.
Market Segmentation: The oral drug delivery segment accounted for the highest share in global castrate resistant prostate cancer therapeutics market.
The castrate-resistant prostate cancer therapeutics market is classified into oral drug delivery methods and injectable drug delivery methods by drug delivery method. The oral drug delivery method contributes a major share of the castrate-resistant prostate cancer therapeutics market. The doctors majorly suggest oral medicines compared to injectables for the treatment of castrate-resistant prostate cancer. The market players have also engaged in marketing oral castrate-resistant prostate cancer therapeutics across the globe.
By therapy type, the castrate-resistant prostate cancer therapeutics market is classified into chemotherapy, hormonal therapy, immunotherapy, and radiotherapy. The hormonal therapy segment held a significant share in the market. Hormone therapy is often regarded as an androgen suppression therapy. The therapy aims to block or lower testosterone in the body to stop it from fueling prostate cancer cells' growth. Lowering androgen levels often makes prostate cancers grow sluggish. Based on drugs' functioning, hormonal therapy is of different types that include orchiectomy and medical castration. Medical castration involves the luteinizing hormone-releasing hormone (LHRH) agonist drugs that lower the amount of testosterone made by the testicles. Leuprolide, Goserelin, Triptorelin, and Histrelin are the commonly used LHRH agonist drugs available in the US market.
Geographical Penetration: North America is the dominating region during the forecast period.
The North American market dominated with the largest market share in the global castrate-resistant prostate cancer therapeutics market in 2019. Factors augmenting the North American market's growth include a significant rise in the incidence and prevalence of prostate cancer and initiatives to create awareness for prostate cancer. For instance, Prostate Cancer Awareness Month is observed in the US and Canada in September every year. Also, the organizations offer grants for prostate cancer research.
Moreover, the Asia Pacific region is expected to grow at the highest CAGR in the global market owing to the high prevalence of prostate cancer in the region coupled with the rapidly evolving healthcare infrastructure in major economies such as China and India are fueling the growth of the castrate-resistant prostate cancer therapeutics market.
The castrate-resistant prostate cancer therapeutics market is dominated by a few companies. Some of the key players in the market's growth include Astellas Pharma, Inc., Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., Sanofi SA, GlaxoSmithKline PLC, Northwest Biotherapeutic, and Active Biotech AB, among others. The key players execute several growth strategies, such as product launches, acquisitions, and collaborations, which are estimated to boost the castrate-resistant prostate cancer therapeutics market growth globally. In May 2020, XTANDI was approved by the Japan Ministry of Health, Labour and Welfare (MHLW), which is used for the treatment of prostate cancer with distant metastasis. XTANDI is the oral androgen receptor signaling inhibitor for the treatment of prostate cancer patients with distant metastasis. In August 2022, FDA approved the expanded use of Buyer's prostate cancer drug. This approval is based on the results of Phase 3 ARASENS trial, which demonstrated a reduction in the risk of death by prostate cancer up to 32% in Nubeqa plus androgen deprivation therapy and docetaxel compared to ADT and docetaxel. Some major players follow acquisition strategies to expand their business. For instance, in June 2021, Bayer Acquired Noria and PSMA Therapeutics to expand its pipeline in prostate cancer. Through this acquisition, the Buyer obtained exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed towards prostate-specific membrane antigen (PSMA).
COVID-19 Impact: Negative impact on the global castrate resistant prostate cancer therapeutics market.
The COVID-19 pandemic outbreak is expected to derail the growth of the castrate-resistant prostate cancer therapeutics market in 2020. The decline in the diagnosis rate due to the downfall in the number of hospital visits is the major factor that has negatively impacted the castrate-resistant prostate cancer therapeutics market growth in 2020.